1. |
Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19(10):1727-33. doi: 10.1093/annonc/mdn351.
doi: 10.1093/annonc/mdn351
pmid: 18515795
|
2. |
Lepage C, Bouvier AM, Phelip JM, et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004; 53(4):549-53. doi: 10.1136/gut.2003.026401.
doi: 10.1136/gut.2003.026401
pmid: 15016750
|
3. |
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.
doi: 10.1200/JCO.2007.15.4377
|
4. |
Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?. Curr Oncol Rep 2021; 23(4):43. doi: 10.1007/s11912-021-01029-7.
doi: 10.1007/s11912-021-01029-7
|
5. |
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3(10):1335-42. doi: 10.1001/jamaoncol.2017.0589.
doi: 10.1001/jamaoncol.2017.0589
|
6. |
Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9, 821 patients. J Gastrointest Surg 2007; 11(11):1460-7; discussion 1467-9. doi: 10.1007/s11605-007-0263-3.
doi: 10.1007/s11605-007-0263-3
|
7. |
Donin N, Filson C, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016; 122(19):3075-86. doi: 10.1002/cncr.30164.
doi: 10.1002/cncr.30164
|
8. |
Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286(8):921-9. doi: 10.1001/jama. 286.8.921.
doi: 10.1001/jama. 286.8.921
|
9. |
Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Clin Oncol 2013; 107(1):1-7. doi: 10.1002/jso.23149.
doi: 10.1002/jso.23149
|
10. |
Shahar T, Nossek E, Steinberg DM, et al. The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci 2012; 19(11):1530-34. doi: 10.1016/j.jocn.2012.04.005.
doi: 10.1016/j.jocn.2012.04.005
pmid: 22989795
|
11. |
Laccetti AL, Pruitt SL, Xuan L, et al. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 2015; 107(4):djv002. doi: 10.1093/jnci/djv002.
doi: 10.1093/jnci/djv002
|
12. |
Laccetti AL, Pruitt SL, Xuan L, et al. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer 2016; 98:106-13. doi: 10.1016/j. lungcan.2016.05.029.
doi: S0169-5002(16)30355-5
pmid: 27393515
|
13. |
Al-Husseini MJ, Saad AM, El-Shewy KM, et al. Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study. Int J Neurosci 2019; 129(5):447-54. doi: 10.1080/00207454.2018.1538989.
doi: 10.1080/00207454.2018.1538989
pmid: 30366515
|
14. |
Duhamel A, Labreuche J, Gronnier C, et al. Statistical tools for propensity score matching. Ann Surg 2017; 265(6):E79-e80. doi: 10.1097/sla.0000000000001312.
doi: 10.1097/sla.0000000000001312
|
15. |
Morgan CJ. Reducing bias using propensity score matching. J Nucl Cardiol 2018; 25(2):404-6. doi: 10.1007/s12350-017-1012-y.
doi: 10.1007/s12350-017-1012-y
|
16. |
Li G, Tian ML, Bing YT, et al. Impact of a prior nonpancreatic malignancy on survival outcomes of patients with stage Ⅳ pancreatic neuroendocrine tumor: a population-based and propensity score matching study. Pancreas 2020; 49(8):1090-8. doi: 10.1097/MPA.0000000000001630.
doi: 10.1097/MPA.0000000000001630
|
17. |
Shen M, Boffetta P, Olsen JH, et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006; 163(6):502-11. doi: 10.1093/aje/kwj073.
doi: 10.1093/aje/kwj073
pmid: 16421239
|
18. |
Sara JS, Lindsay MM, Amy B, et al. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015. Cancer Epidemiol 2020; 64:101664. doi: 10.1016/j.canep.2019.101664.
doi: 10.1016/j.canep.2019.101664
|
19. |
Sung H, Hyun N, Leach CR, et al. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. JAMA 2020; 324(24):2521-35. doi: 10.1001/jama.2020.23130.
doi: 10.1001/jama.2020.23130
|
20. |
Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999; 52(12):1143-56.
pmid: 10580777
|
21. |
Al-Husseini MJ, Saad AM, Turk T, et al. Impact of prior malignancy on survival outcomes of stage Ⅳ pancreatic adenocarcinoma: SEER-Based Cohort. J Gastrointest cancer 2018; 50(4):794-800. doi: 10.1007/s12029-018-0158-4.
doi: 10.1007/s12029-018-0158-4
|
22. |
Jennifer LG. Inherited syndromes involving pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020; 11(3):559-66. doi: 10.21037/jgo.2020.03.09.
doi: 10.21037/jgo.2020.03.09
pmid: 32655935
|
23. |
Oberg K. The genetics of neuroendocrine tumors. Semin Oncol 2013; 40(1):37-44. doi: 10.1053/j.seminoncol.2012.11.005.
doi: 10.1053/j.seminoncol.2012.11.005
|